NASDAQ: RPRX

Royalty Pharma (RPRX) Stock Analysis & Forecast

Nov 16 close

$68.53−0.78 (−1.1%)

Gekko Brief

AI summaryNov 16 close

Royalty Pharma presented at the UBS Global Biopharma Conference on 17 November and continues to draw analyst attention after Q3 royalty receipts rose 9% to $883 million, led by Tremfya, Voranigo, and Evrysdi, with Vertex now accounting for approximately 25% of royalty receipts as newer medicines reduce portfolio concentration. Filings this week also showed Eurizon Capital SGR S.p.A. and Alps Advisors Inc. trimming their positions in RPRX.

RPRX closed at $68.53, down 1.1%, with the close sitting above both the 50-day average of $61.61 and the 200-day average of $54.76, reflecting a supportive longer-term trend. The stock trades within 52-week range of $37.31 to $70.37, with one-year return of 72.5%. The GekkoIndex reads 45.8, placing it in the Neutral zone, while the price sits 21.9% above Gekko Fair Value of $56.22.

The next earnings date falls on 10 February 2027, 85 days out and beyond a typical 20-trading-day holding window; the prior quarter saw an EPS beat of $1.32 versus $1.27 estimated, with a reaction of -0.4%. No insider, Congress, or unusual options activity appears in the respective 90-day and 30-day windows, though one billionaire holder is recorded. Seasonality over the next 20 trading days has averaged -1.9% across 5 years, rising in 1 of them, a pattern worth noting alongside the six analyst firms currently rating the stock buy with a consensus target of $72.

Written by AI from the Nov 16, 2026 close and checked automatically against the figures on this page.

Royalty Pharma price vs fair value

$68.53$56.26Nov ’25May ’26Nov ’26
Close $68.53200-day averageGekko Fair Value $56.26

Royalty Pharma quick facts

Market cap
$30.51B
P/E ratio
45.3
Forward P/E
34.4
EPS, TTM
$1.53
Revenue, TTM
$2.62B
Profit margin
25.7%
Dividend yield
1.35%
Beta
0.36
Volume
3.00M avg 3.39M
1-year return
+72.5%
Typical daily move
±2.5%
Typical 20-day move
±3.9%
50-day average
$61.61
200-day average
$54.76
Next earnings
Feb 10 before open
Shares outstanding
445.3M
52-week range
$37.31$70.37

Royalty Pharma swing-trade checklist

Royalty Pharma scores 2 supportive, 1 mixed and 2 headwinds across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

2 supportive1 mixed2 headwinds

  • Trendsupportive

    Above 50 and 200-day

    Close $68.53 is above the 50-day ($61.61) and 200-day ($54.76) averages, and the 50-day is above the 200-day.

    See the chart
  • GekkoIndexmixed

    45.8, Neutral

    Reading 45.8 is in the Neutral zone.

    See the GekkoIndex
  • Fair valueheadwind

    21.8% above

    Price is 21.8% above Gekko Fair Value (more than 5% above).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 85 days

    Next report Feb 10, 2027, 85 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalityheadwind

    −3.4% on average

    From this point in the calendar, the next 20 trading days averaged −3.4% over 5 years, rising in 1 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Royalty Pharma stock chart and price history

Royalty Pharma closed at $68.53 on Nov 16, 2026, +72.5% over the past year, inside a 52-week range of $37.31 to $70.37.

Close50-day average200-day averageVolume
Royalty Pharma share price, past year, with 50-day and 200-day moving averages and volume$40$50$60DecJan 2026FebMarAprMayJunJulAugSepOctNov68.53

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+12.4%
3 months
+14.8%
6 months
+31.6%
1 year
+72.5%
The full RPRX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open RPRX in Gekko

Follow Royalty Pharma through every session

Put RPRX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track RPRX in GekkoFree for 7 days. No credit card required.

About Royalty Pharma

Royalty Pharma acquires royalty streams tied to biopharmaceutical products rather than developing drugs itself, and in doing so helps finance work across the biopharmaceutical industry in the United States. Its holdings cover rights to roughly 35 therapies already on the market along with around 20 candidates still in development, spanning areas such as rare disease, cancer, neuroscience, infectious disease, blood disorders, and diabetes.

Its business centers on purchasing these royalty interests, which links its earnings to the commercial performance of medicines developed and sold by other companies in the sector rather than to any products it makes or markets directly.

Royalty Pharma traces back to 1996 and operates out of New York, New York. Its shares are listed on the NASDAQ under the ticker RPRX.

Listed
NASDAQ
Sector
Health technology
Industry
Pharmaceuticals: major
Website
royaltypharma.com

Royalty Pharma GekkoIndex: the smart money zone

Royalty Pharma’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 45.8, in the Neutral zone, up 3.4 points over five sessions.

010045.8Neutral

Up 3.4 points over five sessions, from the Distribution zone.

Reading for Nov 16, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying24+1.5%+2.8%+5.4%+15.9%
Accumulation157+0.2%+0.9%+3.1%+6.2%
Neutral (current zone)451+0.8%+1.5%+2.2%+5.8%
Distribution73+0.4%+1.0%+2.9%+4.1%
Selling2Too few readings yet

Average RPRX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the RPRX price, zone by zone.Track RPRX in Gekko

Is Royalty Pharma stock overvalued? Gekko Fair Value

Royalty Pharma trades 21.8% above Gekko Fair Value of $56.26, so the shares are overvalued on Gekko’s estimate.

Gekko’s own estimate of what Royalty Pharma shares are worth, recalculated every trading day.

$56.26

Gekko Fair Value, Nov 17, 2026

21.8% Overvalued

At the end of Aug 2026 the price was 32.9% above the estimate.

Gekko Fair ValueShare price, month end
$56$69Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open RPRX in Gekko

Royalty Pharma insider and Congress trading

No open-market insider purchases were filed for Royalty Pharma, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for RPRX in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every RPRX insider filing, plotted on the chart in Gekko.Open RPRX in Gekko

Congress trades last 90 days

No trades in RPRX were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for RPRX, plotted on the chart in Gekko.Open RPRX in Gekko

Buybacks

Royalty Pharma has been buying back its own shares.

Bought back, quarter ended Sep 30, 2026
$86.34M
As a share of market cap
0.28%
Trailing four quarters
$261.6M

From company filings.

Hedge funds and billionaires quarter ended Sep 30

1of the funds Gekko tracks holds RPRX.

0added0opened1trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko

Royalty Pharma earnings: next date and track record

Royalty Pharma reports on Feb 10, 2027, before the open (85 days away), and beat the EPS estimate in 8 of its last 8 reports.

8 of 8reports beat the EPS estimate
±2.4%average move across the report
4 of 8reports followed by a gain

Share-price move across each report

−3.7%Nov ’24+2.0%Feb ’25+1.2%May ’25−2.4%Aug ’25+7.8%Nov ’25+1.3%Feb ’26−0.5%May ’26−0.4%Aug ’26

Last earnings call, Aug 5, 2026 AI summary

What they said
Royalty Pharma reported Q2 2026 with 6% portfolio receipts growth and 14% total receipts growth, exceeding guidance. ROIC was 14.2% and return on invested equity 20.1%. The company deployed $1.1B in capital YTD with $1.7B announced value, including a key cliramitug royalty acquisition from Neurimmune for up to $425M. Returned ~$370M to shareholders via dividends and buybacks in H1 2026.
Guidance
Management raised 2026 full-year guidance for the second consecutive quarter citing strong business momentum. Deal pipeline described as robust. Regulatory approvals for Trodelvy, Jideytro, and Imdelltra expected to contribute to future top-line growth.
ReportedEPSSurpriseRevenueSurpriseMove
Aug 5, 2026$1.32
est $1.27
+3.9%$773.0M
est $758.9M
+1.9%−0.4%
May 6, 2026$1.30
est $1.18
+10.2%$925.0M
est $881.7M
+4.9%−0.5%
Feb 11, 2026$1.46
est $1.29
+13.2%$874.0M
est $807.0M
+8.3%+1.3%
Nov 5, 2025$1.17
est $0.99
+17.7%$609.3M
est $717.4M
−15.1%+7.8%
Aug 6, 2025$1.14
est $1.03
+10.7%$578.7M
est $673.0M
−14.0%−2.4%
May 8, 2025$1.06
est $0.95
+11.2%$568.2M
est $705.3M
−19.4%+1.2%
Feb 11, 2025$1.15
est $1.05
+9.5%$594.0M
est $687.1M
−13.5%+2.0%
Nov 6, 2024$1.04
est $0.93
+11.8%$564.7M
est $696.9M
−19.0%−3.7%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Royalty Pharma stock forecast and analyst price targets

Analysts’ average 12-month price target for Royalty Pharma is $72.00, +5.1% from the last close, from 6 firms rating the stock in the last 90 days.

$72.00consensus 12-month target, +5.1% from the last close
Low $63High $78
Buy6
Hold0
Sell0

Each firm’s latest rating in the last 90 days: 6 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 5CitiBuy, maintained$78+13.8%
Nov 4J.P. MorganBuy, maintained$74+8.0%
Oct 12CitiBuy, maintained$70+2.1%
Oct 9Bank of America SecuritiesBuy, maintained$63−8.1%
Oct 7Morgan StanleyBuy, reiterated$67−2.2%
+2.2%average 20-day move after past Neutral readings
−3.4%average move over the next 20 trading days in the last 5 years
±2.5%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Royalty Pharma seasonality: the next 20 trading days

Over the next 20 trading days from Nov 17, Royalty Pharma averaged −3.4% across the last 5 years, rising in 1 of them.

Next 20 trading days, by year

−10.0%2021−5.0%2022+2.8%2023−2.6%2024−2.0%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days+1.4%4 of 5
Next 10 trading days+1.1%4 of 5
Next 15 trading days−1.0%2 of 5
Next 20 trading days−3.4%1 of 5
Next 30 trading days−2.2%1 of 5

For scale, RPRX’s typical 20-trading-day move in either direction is about 3.9%.

Royalty Pharma market cap and key statistics

Royalty Pharma’s market cap is $30.51B, with a P/E ratio of 45.3 and revenue of $2.62B over the last twelve months.

Valuation

Market cap
$30.51B
P/E ratio
45.3
Forward P/E
34.4
EPS, TTM
$1.53
Gekko Fair Value
$56.26

Trading

Volume
3.00M
Avg volume, 20 days
3.39M
52-week high
$70.37
52-week low
$37.31
Shares outstanding
445.3M

Financials

Revenue, TTM
$2.62B
Profit margin
25.7%
Return on equity
12.1%
Quarterly earnings growth, YoY
−50.8%

Risk and income

Beta
0.36
Typical daily move
±2.5%
Typical 20-day move
±3.9%
Dividend yield
1.35%

Royalty Pharma stock news this week

5 headlines about Royalty Pharma from the past week, newest first, each linking to the publisher.

Royalty Pharma peers

Royalty Pharma’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
LLYEli Lilly−1.5%Neutral23.2% above
JNJJohnson & Johnson−2.2%Neutral3.6% above
ABBVAbbVie−1.8%Neutral23.4% above
MRKMerck−2.3%Neutral10.0% below
AZNAstraZeneca−1.5%Neutral34.5% below
PFEPfizer−1.3%Accumulation8.0% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Pharmaceuticals: major

Royalty Pharma stock FAQ

What is Royalty Pharma’s market cap?

Royalty Pharma’s market cap is $30.51B at the Nov 16, 2026 close of $68.53, with 445.3M shares outstanding. The shares trade on a P/E ratio of 45.3.

What is the Royalty Pharma stock forecast?

The consensus analyst 12-month price target for Royalty Pharma is $72.00, +5.1% from the last close. Of the 6 firms that rated the stock in the last 90 days, 6 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Royalty Pharma stock overvalued or undervalued?

On Gekko’s estimate Royalty Pharma is overvalued: the Nov 16, 2026 close of $68.53 is 21.8% above Gekko Fair Value of $56.26. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Royalty Pharma report earnings next?

Royalty Pharma is expected to report on Feb 10, 2027, before the market opens (85 days away). Analysts expect earnings of $1.53 per share on revenue of $960.7M. Royalty Pharma beat the earnings estimate in 8 of its last 8 reports, moving 2.4% on average across the report.

What is Royalty Pharma’s 52-week high and low?

Royalty Pharma’s 52-week high is $70.37 and its 52-week low is $37.31; it closed at $68.53 on Nov 16, 2026, +72.5% over the past year.

Is Royalty Pharma stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and earnings risk), 1 as mixed (gekkoindex) and 2 as headwinds (fair value and seasonality). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Royalty Pharma the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,476 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.